Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jena DM + metformin is a combination therapy used in the management of type 2 diabetes mellitus. Jena DM is a licensed herbal formulation in Uganda, primarily containing extracts of Cymbopogon citratus (lemongrass), and is used as a complementary therapy alongside standard oral hypoglycemic agents such as metformin. Metformin is a biguanide antihyperglycemic agent that decreases hepatic glucose production, increases insulin sensitivity, and reduces appetite via GDF15 secretion. The combination aims to improve glycemic control and may have additive effects on weight reduction; however, clinical studies indicate that while Jena DM does not significantly reduce HbA1c when added to metformin, it can lead to modest weight loss but also increases the risk of adverse events such as dizziness and epigastric pain[1][6]. The mechanism of action for Jena DM likely involves phytochemicals with potential hypoglycemic activity from Cymbopogon citratus, though precise molecular targets are not fully characterized.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jena DM + metformin.